Timothy Walbert

Tim Walbert is currently senior advisor, Amgen. Most recently, Mr. Walbert served as the chairman, president and chief executive officer of Horizon Therapeutics from 2008 to October 2023, when it was acquired by Amgen for $28.3 billion. Walbert has been president and CEO since 2008 and chairman since 2010. Prior to Horizon, he was president, CEO and director of IDM Pharma Inc., served as EVP of commercial operations at NeoPharm Inc., and divisional VP and general manager of immunology at Abbott, now AbbVie, where he led the global development and launch of the multi-indication biologic HUMIRA.